{"id":15880,"date":"2018-11-09T08:03:52","date_gmt":"2018-11-09T08:03:52","guid":{"rendered":"https:\/\/celonpharma.com\/?p=15880"},"modified":"2018-11-09T08:03:52","modified_gmt":"2018-11-09T08:03:52","slug":"celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/","title":{"rendered":"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor"},"content":{"rendered":"<ul>\n<li>The Company\u2019s anti-cancer drug \u2013 (CPL304110) \u2013 might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases.<\/li>\n<li>The objective of the trial will be to determine the drug\u2019s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects.<\/li>\n<li>The clinical trial will be held in Poland; the study design was developed and verified in cooperation with key clinicians and toxicologists from Poland, Belgium, Great Britain and the USA.<\/li>\n<li>The Company has also developed its own modern diagnostic tests which will be used to select patients for the first phase of the trial, scheduled to take several months.<\/li>\n<\/ul>\n<p><strong>Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:<\/strong> <em>This is a very important stage for us, we have been preparing for it over the course of several years. We are facing a significant and uneasy challenge, which is the result of i.a. the study design itself and the specific characteristics of patients enrolled in the trial. That is why the trial is implemented in cooperation with key scientific centres in Poland. <\/em><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Company\u2019s anti-cancer drug \u2013 (CPL304110) \u2013 might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases. The objective of the trial will be to determine the drug\u2019s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects. The clinical trial<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\" title=\"ReadCelon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-15880","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"The Company\u2019s anti-cancer drug \u2013 (CPL304110) \u2013 might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases. The objective of the trial will be to determine the drug\u2019s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects. The clinical trialRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-09T08:03:52+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\",\"url\":\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\",\"name\":\"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2018-11-09T08:03:52+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/","og_locale":"en_US","og_type":"article","og_title":"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP","og_description":"The Company\u2019s anti-cancer drug \u2013 (CPL304110) \u2013 might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases. The objective of the trial will be to determine the drug\u2019s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects. The clinical trialRead more &raquo;","og_url":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/","og_site_name":"CelonGROUP","article_published_time":"2018-11-09T08:03:52+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/","url":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/","name":"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2018-11-09T08:03:52+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2018\/11\/09\/celon-pharma-s-a-rozpoczyna-rozwoj-kliniczny-wlasnego-leku-przeciwnowotworowego-nowej-klasy-inhibitora-fgfr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug \u2013 an FGFR inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/15880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=15880"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/15880\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=15880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=15880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=15880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}